BioNet News, Pertussis, Publication 06 Dec 2021 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age Background: A phase 2 randomized-controlled safety and immunogenicity trial evaluating different doses of recombinant acellular pertussis vaccine containing genetically-inactivated pertussis… Supachai
BioNet News, Covid-19, Press Releases 02 Jul 2021 COVALIA study update: first healthy volunteers dosed in needle-free SARS-CoV2 DNA vaccine phase 1 trial Melbourne _ 30th June 2021 – Australian biotech company Technovalia is pleased to announce that the first volunteers have… Supachai
BioNet News, Covid-19, Press Releases 25 Jun 2021 The COVALIA trial has commenced with the first injections of COVIGEN in Australia Partnership to test SARS-CoV2 DNA vaccine in healthy Australians Australian researchers will this week commence the first Phase 1 human… Supachai